SCHEMBL2163909

SCHEMBL2163909

CCOc1cc2nnnc(Nc3ccc(F)c(C(F)(F)F)c3)c2cc1OC

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 16/20 0.52
EPHA2 P29317 1/20 0.52
ERBB2 P04626 2/20 0.52
FBP1 P09467 4/20 0.50
EPHB4 P54760 2/20 0.49
KDR P35968 3/20 0.47
AURKA O14965 1/20 0.47
INSR P06213 1/20 0.47
PDGFRB P09619 1/20 0.47
FLT4 P35916 1/20 0.47
CLK1 P49759 1/20 0.47
TEK Q02763 1/20 0.47
AURKB Q96GD4 1/20 0.47
RIPK2 O43353 1/20 0.47
RET P07949 1/20 0.47
KIF5B P33176 1/20 0.47
NOD1 Q9Y239 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2164193 0.91 EGFR (0.55) EGFREPHA2ERBB2EPHB4KDR
SCHEMBL2165522 0.91 EGFR (0.59) EGFREPHA2ERBB2EPHB4KDR
SCHEMBL2165638 0.89 EGFR (0.51) EGFREPHA2ERBB2FBP1EPHB4
SCHEMBL2165636 0.86 EGFR (0.47) EGFREPHA2ERBB2FBP1EPHB4
SCHEMBL2164641 0.86 FBP1 (0.69) EGFRERBB2FBP1EPHB4KDR
SCHEMBL2165634 0.85 EGFR (0.54) EGFREPHA2ERBB2EPHB4KDR
SCHEMBL2164632 0.84 EGFR (0.51) EGFRERBB2FBP1EPHB4KDR
SCHEMBL2164600 0.83 EGFR (0.66) EGFRERBB2FBP1KDR
Hydrochloric Acid SCHEMBL2164081 0.83 EGFR (0.62) EGFREPHA2ERBB2EPHB4KDR
SCHEMBL2163779 0.82 KDR (0.61) EGFRERBB2FBP1EPHB4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US claimed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US claimed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP claimed
US-8349835-B2 Aromatic ring fused triazine derivatives and uses thereof SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2013-01-08 US disclosed
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2011-07-28 US disclosed
EP-2251332-A1 THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF Shenyang Pharmaceutical University (CN) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183972-A1 AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF KDR, FLT1, FLT4 EGFR 8/4885EPHA2 625/4885ERBB2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.